Table 2.
Patient demographics.
| Parameter | Patient A | Patient B | Patient C | Patient D |
|---|---|---|---|---|
| Age of patient, years | 58 | 50 | 58 | 75 |
| Date of hospital admission | 4-12-20 | 4-7-20 | 4-1-20 | 5-28-20 |
| Date of intubation | 4-13-20 | 4-12-20 | 4-2-20 | 5-29-20 |
| Date of confirmed COVID-19 | 4-12-20 | 4-11-20 | 4-7-20 | 5-28-20 |
| Days intubated before leronlimab treatment | ||||
| Date(s) of leronlimab treatment | 4 | 5 | 15 | 4 |
| Comorbidities | Day 0: 4-17-20 | Day 0: 4-17-20 | Day 0: 4-17-20 | Day 0: 6-2-20 |
| Day 7: 4-24-20 | Dose 2 not given | Day 18: 5-5-20 | Day 10: 6-10-20 | |
| Migraines, ex-smoker (20 pack years, quit 2 years ago) | COPD, OSA | Asbestosis, COPD, ex-smoker (50 pack years), HTN, DM, hypercholesterolemia | Bradycardia, beta thalassemia | |
| DVT | Acute kidney injury, sacral decubitus ulcer | |||
| Concurrent diagnoses during admission | Necrotizing fasciitis of right forearm, acute kidney injury, DVT | DVT, PNA | ||
| Current smoker (2 packs per day) | Ex-smoker | None | ||
| 7 | ||||
| Smoking history | Ex-smoker | HCQ 200 mg po BID x 5 days | 10 | 2 |
| 10 | Tocilizumab, remdesivir | |||
| Onset of symptoms before hospitalization, days | 10 | 4 | Zinc, HCQ, azithromycin | Deceased |
| Other investigational drugs administered | HCQ 200 mg po BID x 5 days | 17 | Deceased | N/A |
| Total days in ICU | 21 | Discharged 5-26-20 | N/A | |
| Days in ICU after leronlimab treatment | 18 | 50 | N/A | |
| Removed from oxygen after receiving leronlimab, days | 19 | N/A | ||
| Discharged status | Discharged 5-19-20 | N/A | N/A | |
| Total days in hospital | 38 | N/A | N/A |
BID, twice daily; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; DVT, deep vein thrombosis; HCQ, hydroxychloroquine; HTN, hypertension; ICU, intensive care unit; N/A, not applicable; OSA, obstructive sleep apnea; po, taken by mouth; PNA, pneumonia.